Jose Manuel Sanchez Lopez

Dr. Jose Manuel Sanchez Lopez

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2025 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
FOFederico Osorio-Antonio
Federico Osorio-Antonio
DDDaniela Michel Diaz-González
Daniela Michel Diaz-González
EBElizabeth Bautista
Elizabeth Bautista
GVGabriela Elizabeth Campos Viguri
Gabriela Elizabeth Campos Viguri
OPOscar Peralta-Zaragoza
Oscar Peralta-Zaragoza
VVVerónica Velázquez-Orozco
Verónica Velázquez-Orozco

Verified
Journal Article
Open access
PDF file
NSNorberto Sánchez-Escobar
Norberto Sánchez-Escobar
MRMaria de los Angeles Romero-Tlalolini
Maria de los Angeles Romero-Tlalolini
HRHaydee Rosas-Vargas
Haydee Rosas-Vargas
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
Juan Carlos Núñez-EnríquezJuan Carlos Núñez-Enríquez
Juan Carlos Núñez-Enríquez
MRMINERVA MATA ROCHA
MINERVA MATA ROCHA
B-lineage acute lymphoblastic leukemia (B-ALL) is classified into more than 20 molecular subtypes, and next-generation sequencing has facilitated the identification of these with high sensitivity. Bulk RNA-seq analysis of bone marrow was realized to identify molecular subtypes in Mexican pediatric patients with B-ALL. High hyperdiploidy (27.3%) was the most frequent molecular subtype, followed by DUX4 (13.6%), TCF3::PBX1 (9.1%), ETV6::RUNX1 (9.1%), Ph-like (9.1%), ETV6::RUNX1-like (9.1%), PAX5alt (4.5%), Ph (4.5%), KMT2A (4.5%), and ZNF384 (4.5%), with one patient presenting both the PAX5alt and low hypodiploidy subtypes (4.5%). The genes TYK2, SEMA6A, FLT3, NRAS, SETD2, JAK2, NT5C2, RAG1, and SPATS2L harbor deleterious missense variants across different B-ALL molecular subtypes. The Ph-like subtype exhibited mutations in STAT2, ADGRF1, TCF3, BCR, JAK2, and NRAS with overexpression of the CRLF2 gene. The DUX4 subtype showed mutually exclusive missense variants in the PDGRFA gene. Here, we have demonstrated the importance of using RNA-seq to facilitate the differential diagnosis of B-ALL with successful detection of gene fusions and mutations. This will aid both patient risk stratification and precision medicine.

9 April 2021 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
EMEdna Ayerim Mandujano-Tinoco
Edna Ayerim Mandujano-Tinoco
AGAlfredo Garcia-Venzor
Alfredo Garcia-Venzor
LLLaura Fatima Lozada-Rodriguez
Laura Fatima Lozada-Rodriguez
CZCECILIA ZAMPEDRI
CECILIA ZAMPEDRI
FLFloria Lizarraga
Floria Lizarraga
BACKGROUND: Long-non-coding RNAs, a class of transcripts with lengths > 200 nt, play key roles in tumour progression. Previous reports revealed that LINC00052 (long intergenic non-coding RNA 00052) was strongly downregulated during breast cancer multicellular spheroids formation and suggested a role in cell migration and oxidative metabolism. OBJECTIVE: To examine the function of LINC00052 in MCF-7 breast cancer cells. METHODS: Loss-of-function studies were performed to evaluate LINC00052 role on MCF-7 breast cancer cells. Microarray expression assays were performed to determine genes and cellular functions modified after LINC00052 knockdown. Next, the impact of LINC00052 depletion on MCF-7 cell respiration and migration was evaluated. RESULTS: 1,081 genes were differentially expressed upon LINC00052 inhibition. Gene set enrichment analysis, Gene Ontology and Key Pathway Advisor analysis showed that signalling networks related to cell migration and oxidative phosphorylation were enriched. However, whereas LINC00052 knockdown in MCF-7 cells revealed marginal difference in oxygen consumption rates when compared with control cells, LINC00052 inhibition enhanced cell migration in vitro and in vivo, as observed using a Zebrafish embryo xenotransplant model. CONCLUSION: Our data show that LINC00052 modulates MCF-7 cell migration. Genome-wide microarray experiments suggest that cancer cell migration is affected by LINC00052 through cytoskeleton modulation and Notch/β-catenin/NF-κB signalling pathways.

Verified
Journal Article
Open access
PDF file
ARAraceli Ruiz
Araceli Ruiz
AGAlfredo Garcia-Venzor
Alfredo Garcia-Venzor
GCGisela Ceballos-Cancino
Gisela Ceballos-Cancino
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
KVKARLA VAZQUEZ-SANTILLAN
KARLA VAZQUEZ-SANTILLAN
VMVilma Maldonado
Vilma Maldonado
Breast cancer is a leading cause of cancer-related deaths among women. Cisplatin is used for treatment, but the development of resistance in cancer cells is a significant concern. This study aimed to investigate changes in the transcriptomes of cisplatin-resistant MCF7 cells. We conducted RNA sequencing of cisplatin-resistant MCF7 cells, followed by differential expression analysis and bioinformatic investigations to identify changes in gene expression and modified signal transduction pathways. We examined the size and quantity of extracellular vesicles. A total of 724 genes exhibited differential expression, predominantly consisting of protein-coding RNAs. Notably, two long non-coding RNAs (lncRNAs), NEAT1 and MALAT, were found to be dysregulated. Bioinformatic analysis unveiled dysregulation in processes related to DNA synthesis and repair, cell cycle regulation, immune response, and cellular communication. Additionally, modifications were observed in events associated with extracellular vesicles. Conditioned media from resistant cells conferred resistance to wild-type cells in vitro. Furthermore, there was an increase in the number of vesicles in cisplatin-resistant cells. Cisplatin-resistant MCF7 cells displayed differential RNA expression, including the dysregulation of NEAT1 and MALAT long non-coding RNAs. Key processes related to DNA and extracellular vesicles were found to be altered. The increased number of extracellular vesicles in resistant cells may contribute to acquired resistance in wild-type cells.

11 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Normand García-HernándezNormand García-Hernández
Normand García-Hernández
Fernando CalzadaFernando Calzada
Fernando Calzada
Elihú BautistaElihú Bautista
Elihú Bautista
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
Miguel ValdesMiguel Valdes
Miguel Valdes
Rosa María Ordoñez-RazoRosa María Ordoñez-Razo
Rosa María Ordoñez-Razo
Background/Objectives: Incomptine A (IA) has cytotoxic activity in non-Hodgkin lymphoma (NHL) cancer cell lines. Its effects on U-937 cells include induction of apoptosis, production of reactive oxygen species, and inhibition of glycolytic enzymes. We examined the altered protein levels present in the lymph nodes of an in vivo mouse model. Methods: We induced an in vivo model with Balb/c mice with U-937 cells and treated it with IA or methotrexate, as well as healthy mice. We determined expressed proteins by TMT based on the LC-MS/MS method (Data are available via ProteomeXchange with identifier PXD060392) and a molecular docking study targeting 15 deregulated proteins. We developed analyses through the KEGG, Reactome, and Gene Ontology databases. Results: A total of 2717 proteins from the axillary and inguinal lymph nodes were analyzed and compared with healthy mice. Of 412 differentially expressed proteins, 132 were overexpressed (FC ≥ 1.5) and 117 were underexpressed (FC ≤ 0.67). This altered expression was associated with 20 significantly enriched processes, including chromatin remodeling, transcription, translation, metabolic and energetic processes, oxidative phosphorylation, glycolysis/gluconeogenesis, cell proliferation, cytoskeletal organization, and with cell death with necroptosis. Conclusions: We confirmed the previously observed dose-dependent effect of IA as a secondary metabolite with important potential as an anticancer agent for the treatment of NHL, showing that the type of drug or the anatomical location influences the response to treatment. The IA promises to be a likely safer and more effective treatment to improve outcomes, reduce toxicities, and improve survival in patients with NHL, initially targeting histones and transcription factors that will affect cell death proteins.

24 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Fernando CalzadaFernando Calzada
Fernando Calzada
Normand García-HernándezNormand García-Hernández
Normand García-Hernández
Elihú BautistaElihú Bautista
Elihú Bautista
JLJose Manuel Sanchez Lopez
Jose Manuel Sanchez Lopez
Miguel ValdesMiguel Valdes
Miguel Valdes
EBELIZABETH BARBOSA
ELIZABETH BARBOSA
Background: Incomptine A (IA) has been reported to have cytotoxic activity in non-Hodgkin lymphoma cancer cell lines and have effects on U-937 cells, including the induction of apoptosis, the production of reactive oxygen species, and the inhibition of glycolytic enzymes. Also, IA has cytotoxic activity in the triple-negative subtypes, HER2+, and luminal A of breast cancer cells, with its properties being associated with an effect on the antiapoptotic function of Hexokinase II (HKII). Objectives: In this research, we reviewed the altered levels of proteins present in the lymph nodes of male Balb/c mice inoculated with U-937 cells and treated with IA or methotrexate, as well as mice only inoculated with cancer cells. Methods: Five approaches, including Tandem Mass Tag (TMT), Gene ontology (GO), Reactome, KEGG pathway analysis, and molecular docking, were used. Results: TMT showed that 74 proteins were differentially expressed, out of which 12 presented overexpression (FC ≥ 1.5) and 62 were under expressed (FC ≤ 0.67). In general, the TMT approach showed that IA had a better effect on proteins than methotrexate. Gene ontology, Reactome, and KEGG pathway analysis showed that proteins with altered levels may be implicated in several processes, including gene silencing by RNA, oxidative phosphorylation, glycolysis/gluconeogenesis, cytoskeleton organization, and ATP metabolic and energetic processes. The molecular docking analysis, which used 23 altered proteins as targets, revealed that IA interacted with all the proteins used. Conclusions: The results obtained using the five bioinformatic approaches provide information and show that IA could be used to treat non-Hodgkin lymphoma induced with the U-937 cell line. Also, it could provide a basis for future research and the development of clinical trials.